Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JBJ-04-125-02 |
Trade Name | |
Synonyms | |
Drug Descriptions |
JBJ-04-125-02 is a next-generation allosteric EGFR inhibitor, which selectively inhibits the kinase activity and activation of EGFR L858R, resulting in reduced cell proliferation, increased apoptosis and tumor growth inhibition (PMID: 31092401). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + JBJ-04-125-02 | Cetuximab JBJ-04-125-02 | 0 | 0 |
JBJ-04-125-02 | JBJ-04-125-02 | 0 | 0 |
JBJ-04-125-02 + Mavelertinib | JBJ-04-125-02 Mavelertinib | 0 | 0 |
JBJ-04-125-02 + Naquotinib | JBJ-04-125-02 Naquotinib | 0 | 0 |
JBJ-04-125-02 + Osimertinib | JBJ-04-125-02 Osimertinib | 0 | 0 |